Mersana Therapeutics Management
Management criteria checks 2/4
Mersana Therapeutics' CEO is Marty Huber, appointed in Sep 2023, has a tenure of 1.25 years. total yearly compensation is $3.04M, comprised of 6.4% salary and 93.6% bonuses, including company stock and options. directly owns 0.094% of the company’s shares, worth $186.13K. The average tenure of the management team and the board of directors is 4.3 years and 7.6 years respectively.
Key information
Marty Huber
Chief executive officer
US$3.0m
Total compensation
| CEO salary percentage | 6.4% |
| CEO tenure | 1.3yrs |
| CEO ownership | 0.09% |
| Management average tenure | 4.3yrs |
| Board average tenure | 7.6yrs |
Recent management updates
Recent updates
Mersana Therapeutics: We're About To Find Out If ADC Platform Is More Tolerable
Dec 19Mersana Therapeutics, Inc.'s (NASDAQ:MRSN) Price Is Right But Growth Is Lacking After Shares Rocket 25%
Dec 01
Is Mersana Therapeutics (NASDAQ:MRSN) Using Debt Sensibly?
Nov 08Mersana Therapeutics, Inc. (NASDAQ:MRSN) Shares Fly 29% But Investors Aren't Buying For Growth
Oct 03Things Look Grim For Mersana Therapeutics, Inc. (NASDAQ:MRSN) After Today's Downgrade
Aug 15Investors Don't See Light At End Of Mersana Therapeutics, Inc.'s (NASDAQ:MRSN) Tunnel And Push Stock Down 32%
Aug 13Mersana Therapeutics, Inc.'s (NASDAQ:MRSN) 25% Dip In Price Shows Sentiment Is Matching Revenues
Jun 19Mersana Therapeutics: On Hold While Waiting For Any Positive News
May 15Investors Don't See Light At End Of Mersana Therapeutics, Inc.'s (NASDAQ:MRSN) Tunnel And Push Stock Down 33%
Apr 25Mersana Therapeutics, Inc.'s (NASDAQ:MRSN) Shares Bounce 26% But Its Business Still Trails The Industry
Feb 27Mersana Therapeutics: A Bottom-Feeding Gamble Of A Stock
Jan 11Here's Why Mersana Therapeutics (NASDAQ:MRSN) Can Manage Its Debt Despite Losing Money
Oct 14Is Mersana Therapeutics (NASDAQ:MRSN) A Risky Investment?
Jun 09Mersana Therapeutics, Inc.'s (NASDAQ:MRSN) Intrinsic Value Is Potentially 22% Below Its Share Price
Feb 22Mersana gains as FDA grants fast track status for breast cancer drug
Sep 12Mersana Therapeutics: Savvy Partnering But Further Progress Is Needed
Aug 15Taking The Measure Of Mersana Therapeutics
Jan 10Mersana: ADC Developer With New INDs, Sufficient Cash, And XMT-1536 Progress
Jun 29It's Unlikely That The CEO Of Mersana Therapeutics, Inc. (NASDAQ:MRSN) Will See A Huge Pay Rise This Year
Jun 05Mersana Therapeutics EPS misses by $0.11, misses on revenue
May 10Is Mersana Therapeutics (NASDAQ:MRSN) A Risky Investment?
Mar 23CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Sep 30 2024 | n/a | n/a | -US$75m |
| Jun 30 2024 | n/a | n/a | -US$105m |
| Mar 31 2024 | n/a | n/a | -US$135m |
| Dec 31 2023 | US$3m | US$194k | -US$172m |
| Sep 30 2023 | n/a | n/a | -US$197m |
| Jun 30 2023 | n/a | n/a | -US$215m |
| Mar 31 2023 | n/a | n/a | -US$213m |
| Dec 31 2022 | US$163k | n/a | -US$204m |
| Sep 30 2022 | n/a | n/a | -US$208m |
| Jun 30 2022 | n/a | n/a | -US$194m |
| Mar 31 2022 | n/a | n/a | -US$183m |
| Dec 31 2021 | US$290k | n/a | -US$170m |
| Sep 30 2021 | n/a | n/a | -US$150m |
| Jun 30 2021 | n/a | n/a | -US$127m |
| Mar 31 2021 | n/a | n/a | -US$106m |
| Dec 31 2020 | US$303k | n/a | -US$88m |
Compensation vs Market: Marty's total compensation ($USD3.04M) is above average for companies of similar size in the US market ($USD1.41M).
Compensation vs Earnings: Marty's compensation has increased whilst the company is unprofitable.
CEO
Marty Huber (63 yo)
1.3yrs
Tenure
US$3,044,085
Compensation
Dr. Martin H. Huber, also known as Marty, M.D., is President and Chief Executive Officer at Mersana Therapeutics, Inc. since September 2023. He served as President and Head of R&D at Xilio Therapeutics, In...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| President | 1.3yrs | US$3.04m | 0.094% $ 186.1k | |
| Senior VP | 5.4yrs | US$1.74m | 0.077% $ 151.7k | |
| Senior VP and Chief Science & Technology Officer | 16.8yrs | US$1.69m | 0.19% $ 377.0k | |
| Senior VP | 3.7yrs | US$1.61m | 0.052% $ 101.9k | |
| Senior VP & Chief Development Officer | 3.2yrs | US$1.58m | 0.044% $ 87.6k | |
| Co-Founder | no data | no data | no data | |
| Chief Accounting Officer | 5.3yrs | no data | 0.039% $ 76.4k | |
| Senior Vice President of Investor Relations & Corporate Communications | no data | no data | no data | |
| Senior Vice President of Regulatory Affairs | 4.3yrs | no data | no data | |
| Exe. Director and Head of Biology | no data | no data | no data |
4.3yrs
Average Tenure
54.5yo
Average Age
Experienced Management: MRSN's management team is considered experienced (4.3 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| President | 4.7yrs | US$3.04m | 0.094% $ 186.1k | |
| Independent Chairman | 12.4yrs | US$329.93k | 0.47% $ 934.1k | |
| Member of the Scientific Advisory Board | no data | no data | no data | |
| Independent Director | 7.3yrs | US$308.93k | 0.0017% $ 3.4k | |
| Independent Director | 6.8yrs | US$305.43k | 0.020% $ 39.6k | |
| Independent Director | 8.3yrs | US$293.43k | 0% $ 0 | |
| Director | 9.8yrs | US$4.65m | 0.34% $ 673.6k | |
| Independent Director | 7.9yrs | US$297.43k | 0% $ 0 | |
| Board Observer | no data | no data | no data | |
| Member of the Scientific Advisory Board | no data | no data | no data | |
| Independent Director | 3.8yrs | US$294.93k | 0% $ 0 | |
| Member of Scientific Advisory Board | no data | no data | no data |
7.6yrs
Average Tenure
60.5yo
Average Age
Experienced Board: MRSN's board of directors are considered experienced (7.6 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/23 10:44 |
| End of Day Share Price | 2024/12/20 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Mersana Therapeutics, Inc. is covered by 18 analysts. 10 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Colleen Kusy | Baird |
| Thomas Shrader | BTIG |
| Justin Zelin | BTIG |